tradingkey.logo

Nexalin Technology Inc

NXLIW
View Detailed Chart

0.049USD

-0.009-18.28%
Close 08/01, 16:00ETQuotes delayed by 15 min
0.00Market Cap
--P/E TTM

Nexalin Technology Inc

0.049

-0.009-18.28%
Intraday
1m
30m
1h
D
W
M
D

Today

-18.28%

5 Days

-28.38%

1 Month

-4.32%

6 Months

-80.18%

Year to Date

-86.09%

1 Year

+Infinity%

View Detailed Chart

Agency Rating

No Data

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

1m
15m
30m
1h
D
W
M
1m
15m
30m
D
Sell
Sell(7)
Neutral(2)
Buy(4)
Indicators
Sell(3)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
-0.001
Sell
RSI(14)
48.793
Neutral
STOCH(KDJ)(9,3,3)
49.101
Sell
ATR(14)
0.029
High Vlolatility
CCI(14)
-38.922
Neutral
Williams %R
39.728
Buy
TRIX(12,20)
-0.932
Sell
StochRSI(14)
100.000
Buy
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
0.047
Buy
MA10
0.047
Buy
MA20
0.061
Sell
MA50
0.063
Sell
MA100
0.081
Sell
MA200
0.183
Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Nexalin Technology, Inc. is engaged in designing and developing neurostimulation products for the mental health epidemic. The Company has developed an easy-to-administer medical device (Generation 1 or Gen-1) that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit a waveform at 4 milliamps during treatment. It also has designed and developed a new advanced waveform technology to be emitted at 15 milliamps through new and improved medical devices referred to as (Generation 2 or Gen-2) and (Generation 3 or Gen-3). Gen-2 is a clinical use device with a modern enclosure to emit the new 15 milliamp advanced waveform. Gen-3 is a new patient headset that will be prescribed by licensed medical professionals in a virtual clinic setting like existing telehealth platforms. Its products are non-invasive and undetectable to the human body.
Ticker SymbolNXLIW
CompanyNexalin Technology Inc
CEOMr. Mark White
Websitehttps://nexalin.com
KeyAI